DAY 1
Public Health Emergency Medical Countermeasures 2004 – 2013 and Beyond
Tuesday, November 12, 2013
AMPHITHEATER

Welcome & Opening Remarks
8:30 am to 8:45 am
Robin Robinson, Ph.D.
Deputy Assistant Secretary for Preparedness and Response
Director, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Keynote Address: BARDA Medical Countermeasures:
Past, Present, and Future
8:45 am to 9:30 am
Robin Robinson, Ph.D.
Deputy Assistant Secretary for Preparedness and Response
Director, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Session 1
BARDA/CBRN: MCM Stockpiling
9:30 am to 10:45 am

Anthrax Vaccines
Eric Espeland, Ph.D.
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Smallpox Vaccines and Antivirals
Gary Disbrow, Ph.D.
Director (Acting), Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Antitoxins Botulism
Melissa Willis, Ph.D.
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Antitoxins Anthrax
Chia-Wei Tsai, Ph.D.
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services
Goal 2: Pathways for MCM Use
### Rad/Nuc
**John Esker, Ph.D.**
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

### Chem (Anticonvulsants)
**Judith Wolfe Laney, Ph.D.**
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

### Biodosimetry
**Rodney Wallace, B.S**  
Chief, Diagnostics & Devices  
Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

---

**AM BREAK**
10:45 am to 11:15 am

---

### Session 2

**BARDA Pandemic Influenza: MCM Stockpiling**
11:15 am to 12:15 pm

**Introduction**
**Robert Huebner, Ph.D.**
Director, Influenza Division  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

**Current Vaccine and Adjuvant Stockpiles**
**Vittoria Cioce, Ph.D.**
Chief, Vaccine Stockpile of Influenza Division  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

**New Approaches to Stockpiling**
**Armen Donabedian, Ph.D.**
Chief, Vaccine Advanced Development Branch of Influenza Division  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

**Other Stockpiles and Conclusions**
**Robert Huebner, Ph.D.**
Director, Influenza Division  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services
Lunch on Your Own  
12:15 pm to 1:30 pm

Session 3  
BARDA/CBRN: FY14 Advanced R&D Priorities  
1:30 pm to 3:00 pm

Broad-Spectrum Antimicrobials  
Joseph Larsen, Ph.D.  
Chief, Broad Spectrum Antimicrobials (BSA) Program  
Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

Viral Hemorrhagic Fever  
Stephen Morris, Ph.D.  
Chief, Antitoxins and Therapeutic Biologics  
Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

Chem Agents  
Judith Wolfe Laney, Ph.D.  
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

Thermal Burns  
Narayan Iyer, Ph.D.  
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

Blood Products  
Brian Tse, Ph.D.  
Program Analyst, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

Biological Diagnostics  
Lynne Wathen, Ph.D.  
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures  
Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services

PM Break  
3:00 pm to 3:30 pm
Session 4

Pandemic Influenza: FY14 Advanced R&D Priorities
3:30 pm to 5:00 pm

Introduction
Rick Bright, Ph.D.
Deputy Director, Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Vaccines with Broader Strain Protection
Armen Donabedian, Ph.D.
Chief, Vaccine Advanced Development Branch of Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Antivirals with Novel Mechanisms of Action
Michael Wathen, Ph.D.
Chief, Antivirals Advanced Development Branch of Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Diagnostics for Identification of Respiratory Pathogens
Roxanne Shively, MS, MT (SM)
Chief, Diagnostics/Devices Advanced Development Branch of Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Improved Respiratory Devices
Robert Huebner, Ph.D.
Director, Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Summary and Conclusions
Rick Bright, Ph.D.
Deputy Director, Influenza Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services
Session 5

BARDA FY14 Product Support Capabilities
08:30 am to 10:30 am

**ADS**
Timothy Lant, Ph.D.
Director, Analytic Decision Support (ADS)
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

**Animal Models**
Adeyinka Smith, M.S
Project Officer, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

**RQA**
Debra Yeskey, Pharm.D.
Director, Regulatory and Quality Affairs Division
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

**Clinical Trials**
Jo-Ellen Schweinle, MD
Senior Program Manager, Division of Clinical Studies
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

**CIADM and Fill/Finish**
Thomas Warf, MS
Director, Manufacturing, Facilities & Engineering
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

**Innovations Program**
Jonathan Seals, Ph.D.
Director, Strategic Science and Technology
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

---

AM Break
10:30 am to 11:00 am
Session 6

Partnering Vehicles to Facilitate Successful Relationships
11:00 am to 12:30 pm

Obtaining Regulatory Guidance from FDA
Alan Liss, Ph.D
Director, MCMi PHSAT
Office of Counterterrorism and Emerging Threats
U.S. Food and Drug Administration

Contracts: RFP vs. BAA
Nathaniel Cohen, J.D.
Contract Specialist
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

IDIQ Contracts
Brooke Bernold, M.S., PMP
Contracting Officer
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

Cooperative Agreements
Barbara Orlando
Grants Management Officer
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

Grants
Barbara Orlando
Grants Management Officer
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

Other Transactions
Glynis M. Fisher, J.D.
Associate Director, Office of Acquisition Management and Policy
Office of the Director, National Institute of Health
U.S. Department of Health and Human Services

Lunch on Your Own
12:30 pm to 1:30 pm
Session 7

Keys to Success in Working with Government Contracts
01:30 pm to 03:00 pm

Small Business
Cassandra Freeman, M.S., M.S.A.
Division Chief, Division of Acquisition Policy
Office of Acquisitions Management, Contracts and Grants
U.S. Department of Health and Human Services

Industry Perspective
Marc S. Ayers
President and Chief Executive Officer
Romark Laboratories L.C

Understanding the TEP
Susan Cortes-Shrank
Contracting Officer
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

In-Process Reviews
Jolinda Summers
Acquisition/Program Management Specialist
BRTRC
Office of Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services

PM Break
3:00 pm to 3:30 pm
Session 8

Keys to Success in Working with Government Contracts cont’d
03:30 pm to 05:00 pm

**EVMS**

*Jason Vettickal*

EVMS SME  
BRTRC  
Office of Acquisition Management, Contracts & Grants  
U.S. Department of Health and Human Services

**Audits**

*Ayhan Akbel, CGAP*

Auditor  
Office of Acquisition Management, Contracts & Grants  
U.S. Department of Health & Human Services

**Invoicing**

*Mathew Rose, J.D.*

Contracting Officer  
Office of Acquisitions Management, Contracts & Grants  
U.S. Department of Health and Human Services

**Online Resources**

*Jolinda Summers*

Acquisition/Program Management Specialist  
BRTRC  
Office of Acquisitions Management, Contracts & Grants  
U.S. Department of Health and Human Services

---

**Closing Remarks**

5:00pm to 5:15pm

*Carol Linden, Ph.D.*

Principal Deputy Director  
Office of Biomedical Advanced Research and Development Authority  
U.S. Department of Health and Human Services
Pre-Scheduled Individual Meetings
8:30 am – 3:00 pm

Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services
&
Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services
Acquisitions Management, Contracts & Grants
U.S. Department of Health and Human Services